Navigation Links
Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
Date:1/3/2008

RESEARCH TRIANGLE PARK, N.C., Jan. 3 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Neil Frazer, M.B., Ch.B., FRCA, FFPM has joined the company as Chief Medical Officer.

Prior to joining Chimerix, Dr. Frazer served as the Chief Medical Officer and Chief Operating Officer of Erimos Pharmaceuticals (previously Biocure Medical) where he was responsible for the design of clinical drug development programs to meet U.S. and global commercial, regulatory and scientific objectives. Prior to his tenure at Erimos, Dr. Frazer served as the Vice President, Clinical Research at Shire Pharmaceuticals where he was responsible for clinical drug development of key programs that included Adderall XR, Equetro and Fosrenol. Dr. Frazer has also held research and development positions at Pharmalink FHI, Medicab, Inc., TabSafe Medical Services, Inc., ClinTrials Research Inc. and Glaxo Wellcome, Inc. Dr. Frazer obtained his B.Sc. and medical degree from the University of Edinburgh Medical School.

"Dr. Frazer's years of research and development experience will be invaluable as we continue to advance our pipeline of orally available and topical antiviral agents through the clinical development process," said Dr. George Painter, Chimerix' President and CEO. "In addition to Dr. Frazer, we have also made a number of key hires in our research and development department, while maintaining our virtual research and development operating model to maintain maximum flexibility and cash efficiency."

With the addition of the new staff, Chimerix currently has 16 full-time employees. To accommodate the new employees, Chimerix has moved its headquarters to 2505 Meridian Parkway, Durham, NC 27713.

About Chimerix

Chimerix, Inc. discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid, prodrug technology, ProLipTag(TM), Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2020)... , ... August 03, 2020 , ... Introducing Ardent Animal ... transformative growth, , Known as MediVet Biologics since its formation ... The new Ardent Animal Health will build on its base of innovative ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... the launch of its new tagline, “BUILDING FOR LIFE.” The adoption of this ... around the globe, requiring fast track capacity to provide patients with urgently needed ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... combine up to three different materials for use with CRM, neurostimulation, vascular, and ... three materials to meet specific design requirements, performance, and cost criteria; especially where ...
(Date:7/31/2020)... ... 2020 , ... eSource has long been touted as the solution to high ... eSource, the reasons it did not take off as quickly as people initially expected, ... is moving towards capturing data electronically for clinical trials and then repurposing it for ...
Breaking Biology Technology:
(Date:8/26/2020)... (PRWEB) , ... August 25, 2020 , ... ... and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health ... 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 ...
(Date:8/23/2020)... ... August 21, 2020 , ... The August edition of ... now available on the company’s global website. Crystallography Times—an electronic newsletter published by ... news and crystallographic research. , The latest issue of Crystallography Times introduces ...
(Date:8/21/2020)... (PRWEB) , ... August 19, 2020 , ... ... Salimetrics LLC and SalivaBio LLC, businesses dedicated to Salivary Bioscience for more than ... the recently published book by Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva ...
Breaking Biology News(10 mins):